Literature DB >> 17553059

The oncogenic potential of human papillomaviruses: a review on the role of host genetics and environmental cofactors.

V K Madkan1, R H Cook-Norris, M C Steadman, A Arora, N Mendoza, S K Tyring.   

Abstract

Human papillomaviruses (HPVs), with over 100 genotypes, are a very complex group of human pathogenic viruses. In most cases, HPV infection results in benign epithelial proliferations (verrucae). However, oncogenic types of HPV may induce malignant transformation in the presence of cofactors. For example, over 99% of all cervical cancers and a majority of vulval, vaginal, anal and penile cancers are the result of oncogenic HPV types. Such HPV types have been increasingly linked to other epithelial cancers involving the skin, larynx and oesophagus. Although viral infection is necessary for neoplastic transformation, evidence suggests that host and environmental cofactors are also required. Research investigating HPV oncogenesis is complex and quite extensive. The inability to produce mature HPV virions in animal models has been a major limitation in fully elucidating the oncogenic potential and role of associated cofactors in promoting malignant transformation in HPV-infected cells. We have reviewed the literature and provide a brief account of the current understanding of HPV oncogenesis, emphasizing the role of genetic susceptibility, immune response, and environmental and infectious cofactors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17553059     DOI: 10.1111/j.1365-2133.2007.07961.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  17 in total

Review 1.  An alternative approach to medical genetics based on modern evolutionary biology. Part 4: HERVs in cancer.

Authors:  Frank P Ryan
Journal:  J R Soc Med       Date:  2009-11       Impact factor: 5.344

2.  Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.

Authors:  Alain Luxembourg; Darron Brown; Celine Bouchard; Anna R Giuliano; Ole-Erik Iversen; Elmar A Joura; Mary E Penny; Jaime A Restrepo; Josefina Romaguera; Roger Maansson; Erin Moeller; Michael Ritter; Joshua Chen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Epidermoid cancer of the anal canal.

Authors:  Shawn P Webb; Chong S Lee
Journal:  Clin Colon Rectal Surg       Date:  2011-09

4.  Concomitant anal and cervical human papillomavirusV infections and intraepithelial neoplasia in HIV-infected and uninfected women.

Authors:  Nancy A Hessol; Elizabeth A Holly; Jimmy T Efird; Howard Minkoff; Kathleen M Weber; Teresa M Darragh; Robert D Burk; Howard D Strickler; Ruth M Greenblatt; Joel M Palefsky
Journal:  AIDS       Date:  2013-07-17       Impact factor: 4.177

5.  Functional implications of mitochondrial reactive oxygen species generated by oncogenic viruses.

Authors:  Young Bong Choi; Edward William Harhaj
Journal:  Front Biol (Beijing)       Date:  2014-12

6.  IGF1 mRNA isoform expression in the cervix of HPV-positive women with pre-cancerous and cancer lesions.

Authors:  Maria Magdalena Koczorowska; Anna Kwasniewska; Anna Gozdzicka-Jozefiak
Journal:  Exp Ther Med       Date:  2010-12-02       Impact factor: 2.447

Review 7.  Immunology and Immunotherapy of Head and Neck Cancer.

Authors:  Robert L Ferris
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

8.  Immunosuppressive tumor microenvironment in cervical cancer patients.

Authors:  Sytse J Piersma
Journal:  Cancer Microenviron       Date:  2011-05-31

9.  The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer.

Authors:  Klaus Friese; Bernd Kost; Aurelia Vattai; Frederik Marmé; Christina Kuhn; Sven Mahner; Christian Dannecker; Udo Jeschke; Sabine Heublein
Journal:  J Cancer Res Clin Oncol       Date:  2017-09-18       Impact factor: 4.553

Review 10.  Human papillomavirus vaccination in HIV-infected women: need for increased coverage.

Authors:  Erna Milunka Kojic; Aadia I Rana; Susan Cu-Uvin
Journal:  Expert Rev Vaccines       Date:  2015-11-24       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.